EP3703681A4 - Imipridones for gliomas - Google Patents

Imipridones for gliomas Download PDF

Info

Publication number
EP3703681A4
EP3703681A4 EP18872950.3A EP18872950A EP3703681A4 EP 3703681 A4 EP3703681 A4 EP 3703681A4 EP 18872950 A EP18872950 A EP 18872950A EP 3703681 A4 EP3703681 A4 EP 3703681A4
Authority
EP
European Patent Office
Prior art keywords
imipridones
gliomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18872950.3A
Other languages
German (de)
French (fr)
Other versions
EP3703681A1 (en
Inventor
Joshua E. Allen
Martin Stogniew
Varun Vijay PRABHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoceutics Inc
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of EP3703681A1 publication Critical patent/EP3703681A1/en
Publication of EP3703681A4 publication Critical patent/EP3703681A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP18872950.3A 2017-11-03 2018-11-05 Imipridones for gliomas Pending EP3703681A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581478P 2017-11-03 2017-11-03
US15/947,840 US10172862B2 (en) 2017-01-30 2018-04-08 Imipridones for gliomas
PCT/US2018/059209 WO2019090222A1 (en) 2017-11-03 2018-11-05 Imipridones for gliomas

Publications (2)

Publication Number Publication Date
EP3703681A1 EP3703681A1 (en) 2020-09-09
EP3703681A4 true EP3703681A4 (en) 2021-08-11

Family

ID=63038820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18872950.3A Pending EP3703681A4 (en) 2017-11-03 2018-11-05 Imipridones for gliomas

Country Status (14)

Country Link
US (4) US10172862B2 (en)
EP (1) EP3703681A4 (en)
JP (2) JP7319989B2 (en)
KR (1) KR20200117979A (en)
CN (2) CN116173036A (en)
AU (1) AU2018360752A1 (en)
BR (1) BR112020008791A2 (en)
CA (1) CA3080815A1 (en)
EA (1) EA202090928A1 (en)
IL (1) IL274194A (en)
MA (1) MA50533A (en)
MX (2) MX2020004375A (en)
SG (1) SG11202003952YA (en)
WO (1) WO2019090222A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009227A (en) 2016-01-29 2018-11-09 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones.
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
WO2020172485A1 (en) * 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
EP4192467A1 (en) 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
CN113248465B (en) * 2021-06-16 2021-10-29 中国农业科学院北京畜牧兽医研究所 Synthetic method of biochanin A
CN114632088B (en) * 2022-05-16 2022-08-16 北京市神经外科研究所 Application of cytarabine compound in preparation of medicine for treating glioma
WO2024030645A1 (en) * 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
CN117731654B (en) * 2024-02-18 2024-05-07 首都医科大学附属北京天坛医院 New application of JJH201601 in treatment of primary glioma and recurrent glioma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1638178A (en) * 1924-11-04 1927-08-09 Union Switch & Signal Co Railway-traffic-controlling apparatus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
AU2008302345A1 (en) * 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
CA2841142C (en) * 2010-06-23 2020-12-15 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
JP2014509323A (en) 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ Treatment of cancer with dopamine receptor blockers
EP4335511A3 (en) 2011-04-29 2024-05-15 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
WO2015073072A1 (en) 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
JP6446025B2 (en) * 2013-03-13 2018-12-26 オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． Compounds for drug combination therapy for cancer
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
US9688679B2 (en) * 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
BR112016011072B1 (en) * 2013-11-15 2022-06-21 Oncoceutics, Inc. 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONA E COMPOUND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUND
JP6756435B2 (en) 2014-03-31 2020-09-16 ザ スクリプス リサーチ インスティテュート Pharmacophore for TRAIL induction
CN104860948B (en) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 Imidazopyrimidine ketone compounds and its preparation method and application
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma", 14 July 2017 (2017-07-14), XP002803516, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT03134131?V_2=View#StudyPageTop> *
ANONYMOUS: "ONC201 in Adults With Recurrent H3 K27M High-grade Glioma", 31 October 2017 (2017-10-31), XP002803515, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT03295396?V_3=View#StudyPageTop> *
ANONYMOUS: "Oral ONC201 in Adult Recurrent Glioblastoma", 19 March 2017 (2017-03-19), XP002803514, Retrieved from the Internet <URL:https://www.clinicaltrials.gov/ct2/history/NCT02525692?V_8=View#StudyPageTop> *
JESSICA WAGNER ET AL: "Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212", CELL CYCLE, vol. 16, no. 19, 2 October 2017 (2017-10-02), US, pages 1790 - 1799, XP055770525, ISSN: 1538-4101, DOI: 10.1080/15384101.2017.1325046 *
KOKI AIHARA ET AL: "H3F3A K27M mutations in thalamic gliomas from young adult patients", NEURO-ONCOLOGY, vol. 16, no. 1, 26 November 2013 (2013-11-26), US, pages 140 - 146, XP055410007, ISSN: 1522-8517, DOI: 10.1093/neuonc/not144 *
MADHUKAR NEEL ET AL: "Abstract 2792: The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway | Cancer Research", CANCER RESEARCH, 1 July 2017 (2017-07-01), XP055820090, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/77/13_Supplement/2792> [retrieved on 20210701] *
PRABHU VIJAY VARUN ET AL: "Abstract 4147A: Potent anti-cancer activity of the imipridone ONC206: A selective dopamine D2-like receptor antagonist | Cancer Research", EXPERIMENTAL AND MOLECULAR THERAPEUTICS, 1 July 2017 (2017-07-01), XP055820088, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/77/13_Supplement/4147A> [retrieved on 20210701] *

Also Published As

Publication number Publication date
CN111818919A (en) 2020-10-23
US10172862B2 (en) 2019-01-08
US20200022982A1 (en) 2020-01-23
BR112020008791A2 (en) 2020-10-20
EA202090928A1 (en) 2020-08-14
US20190183895A1 (en) 2019-06-20
CA3080815A1 (en) 2019-05-09
US10369154B2 (en) 2019-08-06
MX2023013341A (en) 2023-11-27
JP2021502417A (en) 2021-01-28
IL274194A (en) 2020-06-30
JP2023139152A (en) 2023-10-03
US20210236499A1 (en) 2021-08-05
US10946022B2 (en) 2021-03-16
WO2019090222A1 (en) 2019-05-09
AU2018360752A1 (en) 2020-05-21
KR20200117979A (en) 2020-10-14
MA50533A (en) 2020-09-09
CN116173036A (en) 2023-05-30
US20180221375A1 (en) 2018-08-09
EP3703681A1 (en) 2020-09-09
SG11202003952YA (en) 2020-05-28
MX2020004375A (en) 2020-11-11
JP7319989B2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
EP3692489A4 (en) Quantumproof blockchain
EP3645618A4 (en) Polyolefincomposition
EP3703681A4 (en) Imipridones for gliomas
EP3589248A4 (en) Cryotherapies
EP3707858A4 (en) Blockchain system
EP3695118A4 (en) Micro-propulsion system
EP3574400A4 (en) Cyber-retro-reflector technology
EP3684343A4 (en) Improved supraparticles
EP3688700A4 (en) Message-credentialed blockchains
EP3707684A4 (en) Limited scope blockchain system
EP3665276A4 (en) Improved endoinulinases
EP3596929A4 (en) Shoutcasting
EP3598407A4 (en) System
EP3524656A4 (en) Novel hydrogelator
EP3585947A4 (en) Embanking arrangement
EP3486982A4 (en) Structure
EP3550018A4 (en) NOVEL ENDO-ß-N-ACETYLGLUCOSAMINIDASE
AU2016363347B2 (en) Marking-out aid
EP3685644B8 (en) Rfid-carrel
EP3730143A4 (en) Omidenepag combination
EP3682020A4 (en) Sequence-detection system
AU2017904707A0 (en) Humelove
AU2017904592A0 (en) Picaccia
AU2017904507A0 (en) foncph
AU2017904434A0 (en) LifeLessons

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200528

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031418800

Ipc: A61K0031519000

A4 Supplementary search report drawn up and despatched

Effective date: 20210714

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101AFI20210707BHEP

Ipc: A61K 31/4188 20060101ALI20210707BHEP

Ipc: A61K 31/4545 20060101ALI20210707BHEP

Ipc: A61P 35/00 20060101ALI20210707BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240426